Advertisement

Therapeutic Aspects and Diagnosis of the Attention Deficit Hyperactivity Disorder—ADHD in Adults

  • Samuell FerreiraEmail author
  • Rubens Zeron
  • Guilherme Carvalho
  • Lara Gandra
  • Victoria Carestiato
  • Allice Bastos
  • Juliana Silva
  • Adnan Mujanović
Conference paper
Part of the IFMBE Proceedings book series (IFMBE, volume 73)

Abstract

Attention Deficit Hyperactivity Disorder (ADHD) is characterized by difficulties in modulating attention and hyperactivity/impulsivity. It is a very common disorder in childhood compromising school performance, hampering interpersonal relationships and causing low self-esteem that can continue in adult life and bring even more damage to the execution of routine activities in patients lives. The most commonly used treatment for ADHD is through psychostimulant drugs, however, association with other therapies is important to ameliorate the symptoms of hyperactivity. There by the treatment should be multidisciplinary, where several professionals with the family should be accompanying and treating individuals with ADHD. The objective of this study was to highlight the importance of early diagnosis and the contribution of knowledge acquisition on the nuances in the diagnosis of ADHD in adults even during medical training and multidisciplinary therapeutic procedures to improve the symptoms of adult patients with ADHD. It is concluded that the pharmacological treatment is quite effective, mainly regarding the use of methylphenidate as psychostimulant, presenting a very satisfactory profile of side effects. In some individuals with the disorder, pharmacological treatment is not sufficient because the symptoms persist or there are comorbidities. In these cases, multidisciplinary treatment with psychopharmaceuticals, psychotherapies, school and family follow-up is necessary to alleviate symptoms, leading individuals with ADHD to participate in activities common to all in the family and in society, thus preventing conduct disorders and delinquency. Therefore, the early diagnosis of ADHD with a correct treatment institution is essential for a better prognosis of the patient.

Keywords

Attention deficit disorder Hyperactivity Treatment Adult 

Notes

Conflict of Interest

None.

References

  1. 1.
    Farré-Riba, A., Narbona, J.: EDAH: Escala para la evaluación del trastorno por deficit de atención con hiperactividad. TEA, Madrid (2001)Google Scholar
  2. 2.
    American Psychiatric Association: DSM-5. Manual diagnóstico e estatístico de transtornos mentais, 5 edn. (2014). ISBN 9788582710883 Google Scholar
  3. 3.
    Silva, A.B.B.: Mentes inquietas: entendendo melhor o mundo das pessoas distraídas, impulsivas e hiperativas. Napedes, Rio de Janeiro (2003)Google Scholar
  4. 4.
    Bastos, F.L., Thompson, T.A., Martinez, O.C.A.: Uma revisão do distúrbio de Déficit de Atenção/Hiperatividade. Apresentado no 1º Encontro Brasileiro de Neurologia, Outubro de 2000Google Scholar
  5. 5.
    Gomes, M., Palmini, A., Barbirato, F., Rohde, L.A., Mattos, P.: Conhecimento sobre o transtorno de déficit de atenção/hiperatividade no Brasil. J. Bras. Psiquiatr. 56(2), 94–101 (2007)CrossRefGoogle Scholar
  6. 6.
    Antoniuk, S.A.: Transtorno de Déficit de Atenção e Hiperatividade Conceitos e dilemas. J. Paranaense Pediatr. 3(1) (2002)Google Scholar
  7. 7.
    Popper, C.: Antidepressants in the treatment of attention-deficit/hyperactivity disorder. J. Clin. Psychiatry 58(suppl 14), 14–29 (1997)Google Scholar
  8. 8.
    Smith, C.: Dificuldades de Aprendizagem de A a Z, 1 edn. Ed. Artes Médicas (2001)Google Scholar
  9. 9.
    Brazilian Association of Deficit of Attention—ABDA. https://tdah.org.br/depressao-e-tdah-parte-i/ (2016). Accessed 20 Aug 2018
  10. 10.
    Connor, D.F.: Preschool attention deficit hyperactivity disorder: a review of prevalence, diagnosis, neurobiology, and stimulant treatment. J. Dev. Behav. Pediatr. 23, S1–S9 (2002)CrossRefGoogle Scholar
  11. 11.
    Ritalina ® e Ritalina ® LA (coridrato de metilfenidato); Novartis Biociência SA; comprimidos 10 mg, pápsulas 10, 20, 30 ou 40 mg. Anvisa. http://www.anvisa.gov.br/datavisa/fila_bula/frmVisualizarBula.asp?pNuTransacao=24848562016&pIdAnexo=4017454 (2016). Accessed 20 Aug 2018

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Samuell Ferreira
    • 1
    Email author
  • Rubens Zeron
    • 1
  • Guilherme Carvalho
    • 1
  • Lara Gandra
    • 1
  • Victoria Carestiato
    • 1
  • Allice Bastos
    • 1
  • Juliana Silva
    • 1
  • Adnan Mujanović
    • 1
  1. 1.ItaperunaBrazil

Personalised recommendations